

Erythropoietin production potentiator

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 21	IPC search and display fields enhanced in CA/CaPlus with the IPC reform
NEWS	4	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2
NEWS	5	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	6	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	7	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	8	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	9	JAN 30	Saved answer limit increased
NEWS	10	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS	11	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	12	FEB 22	Status of current WO (PCT) information on STN
NEWS	13	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	14	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	15	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	16	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	17	FEB 28	TOXCENTER reloaded with enhancements
NEWS	18	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	19	MAR 01	INSPEC reloaded and enhanced
NEWS	20	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	21	MAR 08	X.25 communication option no longer available after June 2006
NEWS	22	MAR 22	EMBASE is now updated on a daily basis

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

Erythropoietin production potentiator

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:12:57 ON 23 MAR 2006

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:13:05 ON 23 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 MAR 2006 HIGHEST RN 877591-95-2

DICTIONARY FILE UPDATES: 21 MAR 2006 HIGHEST RN 877591-95-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10607996.str



chain nodes :

30 31 32 33 34 35 36 37 38 39 40 41

ring nodes :

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

ring/chain nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

Erythropoietin production potentiator

1-27 6-23 14-34 15-32 16-30 19-40 20-38 21-36 30-31 32-33 34-35 36-37
38-39 40-41
ring/chain bonds :
1-2 2-3 3-4 4-5 5-11 6-7 7-8 8-9 9-10 10-12
ring bonds :
11-13 11-17 12-18 12-22 13-14 14-15 15-16 16-17 18-19 19-20 20-21 21-22
23-24 23-29 24-25 25-26 26-27 27-28 28-29
exact/norm bonds :
1-2 1-27 2-3 3-4 4-5 5-11 6-7 6-23 7-8 8-9 9-10 10-12 14-34 15-32
16-30 19-40 20-38 21-36 23-24 23-29 24-25 25-26 26-27 27-28 28-29 30-31
32-33 34-35 36-37 38-39 40-41
normalized bonds :
11-13 11-17 12-18 12-22 13-14 14-15 15-16 16-17 18-19 19-20 20-21 21-22

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom
19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom
28:Atom 29:Atom 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS
36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS

L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 09:13:48 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 74 TO ITERATE

100.0% PROCESSED 74 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 964 TO 1996

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> D l2 1-2 full

'FULL' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names

Erythropoietin production potentiator

SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties
EPROP - Table of experimental properties
PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):fide

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN
RN 203721-89-5 REGISTRY
ED Entered STN: 07 Apr 1998
CN 1H-1,4-Diazepine, hexahydro-1,4-bis[(3',4',5'-trimethoxy[1,1'-biphenyl]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C37 H40 N2 O8
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)


Ring System Data

Elemental	Elemental	Size of	Ring System	Ring	RID
-----------	-----------	---------	-------------	------	-----


Erythropoietin production potentiator

Analysis EA	Sequence ES	the Rings SZ	Formula RF	Identifier RID	Occurrence Count
C6	C6	6	C6	46.150.18	4
C5N2	NC2NC3	7	C5N2	110.130.1	1

PAGE 1-A



PAGE 2-A



Predicted Properties (PPROP)

PROPERTY (CODE)	VALUE	CONDITION	NOTE
=====	=====	=====	=====

Erythropoietin production potentiator

Bioconc. Factor (BCF)	27.47	pH 1 25 deg C	(1)
Bioconc. Factor (BCF)	27.67	pH 2 25 deg C	(1)
Bioconc. Factor (BCF)	27.69	pH 3 25 deg C	(1)
Bioconc. Factor (BCF)	27.69	pH 4 25 deg C	(1)
Bioconc. Factor (BCF)	27.69	pH 5 25 deg C	(1)
Bioconc. Factor (BCF)	27.69	pH 6 25 deg C	(1)
Bioconc. Factor (BCF)	27.69	pH 7 25 deg C	(1)
Bioconc. Factor (BCF)	27.69	pH 8 25 deg C	(1)
Bioconc. Factor (BCF)	27.69	pH 9 25 deg C	(1)
Bioconc. Factor (BCF)	27.69	pH 10 25 deg C	(1)
Boiling Point (BP)	772.5+/-60.0 deg C	760 Torr	(1)
Density (DEN)	1.197+/-0.06 g/cm**3	760 Torr	(1)
Enthalpy of Vap. (HVAP)	112.44+/-3.0 kJ/mol	760 Torr	(1)
Flash Point (FP)	421.0+/-32.9 deg C		(1)
Freely Rotatable Bonds (FRB)	10		(1)
H acceptors (HAC)	10		(1)
H donors (HD)	0		(1)
Hydrogen Donors/Acceptors Sum (HDAS)	10		(1)
Koc (KOC)	371.79	pH 1 25 deg C	(1)
Koc (KOC)	374.47	pH 2 25 deg C	(1)
Koc (KOC)	374.74	pH 3 25 deg C	(1)
Koc (KOC)	374.77	pH 4 25 deg C	(1)
Koc (KOC)	374.77	pH 5 25 deg C	(1)
Koc (KOC)	374.77	pH 6 25 deg C	(1)
Koc (KOC)	374.77	pH 7 25 deg C	(1)
Koc (KOC)	374.77	pH 8 25 deg C	(1)
Koc (KOC)	374.77	pH 9 25 deg C	(1)
Koc (KOC)	374.77	pH 10 25 deg C	(1)
logD (LOGD)	2.20	pH 1 25 deg C	(1)
logD (LOGD)	2.20	pH 2 25 deg C	(1)
logD (LOGD)	2.20	pH 3 25 deg C	(1)
logD (LOGD)	2.20	pH 4 25 deg C	(1)
logD (LOGD)	2.20	pH 5 25 deg C	(1)
logD (LOGD)	2.20	pH 6 25 deg C	(1)
logD (LOGD)	2.20	pH 7 25 deg C	(1)
logD (LOGD)	2.20	pH 8 25 deg C	(1)
logD (LOGD)	2.20	pH 9 25 deg C	(1)
logD (LOGD)	2.20	pH 10 25 deg C	(1)
logP (LOGP)	2.201+/-0.582	25 deg C	(1)
Mass Intrinsic Solubility (SLB.MASS)	0.021 g/L	25 deg C	(1)
Mass Solubility (SLB.MASS)	0.022 g/L	pH 1 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.021 g/L	pH 2 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.021 g/L	pH 3 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.021 g/L	pH 4 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.021 g/L	pH 5 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.021 g/L	pH 6 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.021 g/L	pH 7 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.021 g/L	pH 8 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.021 g/L	pH 9 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.021 g/L	pH 10 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.021 g/L	Unbuffered Water	(1)
		pH 7.00	
Molar Intrinsic Solubility (ISLB.MOL)	0.000033 mol/L	25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000034 mol/L	pH 1 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000033 mol/L	pH 2 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000033 mol/L	pH 3 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000033 mol/L	pH 4 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000033 mol/L	pH 5 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000033 mol/L	pH 6 25 deg C	(1)

Erythropoietin production potentiator

Molar Solubility (SLB.MOL)	0.000033 mol/L	pH 7 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000033 mol/L	pH 8 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000033 mol/L	pH 9 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000033 mol/L	pH 10 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000033 mol/L	Unbuffered Water	(1)
		pH 7.00	
		25 deg C	
Molar Volume (MVOL)	534.9+/-3.0 cm**3/mol	20 deg C	(1)
		760 Torr	
Molecular Weight (MW)	640.72		(1)
pKa (PKA)	-1.09+/-0.20	Most Basic	(1)
		25 deg C	
Polar Surface Area (PSA)	96.00 A**2		(1)
Vapor Pressure (VP)	8.69E-24 Torr	25 deg C	(1)

(1) Calculated using Advanced Chemistry Development (ACD/Labs) Software V8.14
((C) 1994-2006 ACD/Labs)

See HELP PROPERTIES for information about property data sources in REGISTRY.

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN

RN 191089-59-5 REGISTRY

ED Entered STN: 11 Jul 1997

CN 1H-1,4-Diazepine, hexahydro-1,4-bis[(4E)-5-(3,4,5-trimethoxyphenyl)-4-pentenyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-1,4-Diazepine, hexahydro-1,4-bis[5-(3,4,5-trimethoxyphenyl)-4-pentenyl]-, (E,E)-

OTHER NAMES:

CN K 7174

FS STEREOSEARCH

DR 286441-08-5

MF C33 H48 N2 O6

CI COM

SR CA

LC STN Files: BIOSIS, CA, CAPLUS, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)


RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

Ring System Data

Elemental Analysis	Elemental Sequence	Size of the Rings	Ring System Formula	Ring Identifier	RID Occurrence Count
EA	ES	SZ	RF	RID	
C6	C6	6	C6	46.150.18	2
C5N2	NC2NC3	7	C5N2	110.130.1	1

Double bond geometry as shown.

Erythropoietin production potentiator



the instant compound

Predicted Properties (PPROP)

PROPERTY (CODE)	VALUE	CONDITION	NOTE
Bioconc. Factor (BCF)	1.0	pH 1 25 deg C	(1)
Bioconc. Factor (BCF)	1.0	pH 2 25 deg C	(1)
Bioconc. Factor (BCF)	1.0	pH 3 25 deg C	(1)
Bioconc. Factor (BCF)	1.11	pH 4 25 deg C	(1)
Bioconc. Factor (BCF)	3.30	pH 5 25 deg C	(1)
Bioconc. Factor (BCF)	21.66	pH 6 25 deg C	(1)
Bioconc. Factor (BCF)	192.11	pH 7 25 deg C	(1)
Bioconc. Factor (BCF)	1635.87	pH 8 25 deg C	(1)
Bioconc. Factor (BCF)	6892.98	pH 9 25 deg C	(1)
Bioconc. Factor (BCF)	10165.16	pH 10 25 deg C	(1)
Boiling Point (BP)	689.9+/-55.0 deg C	760 Torr	(1)
Density (DEN)	1.074+/-0.06 g/cm**3	760 Torr	(1)
Enthalpy of Vap. (HVAP)	101.11+/-3.0 kJ/mol	760 Torr	(1)
Flash Point (FP)	171.2+/-28.7 deg C		(1)
Freely Rotatable Bonds (FRB)	16		(1)
H acceptors (HAC)	8		(1)
H donors (HD)	0		(1)
Hydrogen Donors/Acceptors Sum (HDAS)	8		(1)
Koc (KOC)	2.12	pH 1 25 deg C	(1)
Koc (KOC)	2.13	pH 2 25 deg C	(1)
Koc (KOC)	2.19	pH 3 25 deg C	(1)
Koc (KOC)	2.77	pH 4 25 deg C	(1)
Koc (KOC)	8.20	pH 5 25 deg C	(1)
Koc (KOC)	53.89	pH 6 25 deg C	(1)
Koc (KOC)	477.91	pH 7 25 deg C	(1)
Koc (KOC)	4069.57	pH 8 25 deg C	(1)
Koc (KOC)	17147.75	pH 9 25 deg C	(1)
Koc (KOC)	25287.97	pH 10 25 deg C	(1)
logD (LOGD)	1.51	pH 1 25 deg C	(1)
logD (LOGD)	1.51	pH 2 25 deg C	(1)
logD (LOGD)	1.52	pH 3 25 deg C	(1)
logD (LOGD)	1.62	pH 4 25 deg C	(1)
logD (LOGD)	2.09	pH 5 25 deg C	(1)
logD (LOGD)	2.91	pH 6 25 deg C	(1)
logD (LOGD)	3.86	pH 7 25 deg C	(1)
logD (LOGD)	4.79	pH 8 25 deg C	(1)
logD (LOGD)	5.41	pH 9 25 deg C	(1)
logD (LOGD)	5.58	pH 10 25 deg C	(1)
logP (LOGP)	5.607+/-0.446	25 deg C	(1)

Erythropoietin production potentiator

Mass Intrinsic Solubility (ISLB.MASS)	0.00080 g/L	25 deg C	(1)
Mass Solubility (SLB.MASS)	10 g/L	pH 1 25 deg C	(1)
Mass Solubility (SLB.MASS)	10 g/L	pH 2 25 deg C	(1)
Mass Solubility (SLB.MASS)	10 g/L	pH 3 25 deg C	(1)
Mass Solubility (SLB.MASS)	8.0 g/L	pH 4 25 deg C	(1)
Mass Solubility (SLB.MASS)	2.7 g/L	pH 5 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.40 g/L	pH 6 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.046 g/L	pH 7 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.0054 g/L	pH 8 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.0013 g/L	pH 9 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.00085 g/L	pH 10 25 deg C	(1)
Mass Solubility (SLB.MASS)	0.0025 g/L	Unbuffered Water	(1)
		pH 8.43	
Molar Intrinsic Solubility (ISLB.MOL)	0.0000014 mol/L	25 deg C	(1)
Molar Solubility (SLB.MOL)	0.018 mol/L	pH 1 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.018 mol/L	pH 2 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.018 mol/L	pH 3 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.014 mol/L	pH 4 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.0047 mol/L	pH 5 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.00071 mol/L	pH 6 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.000081 mol/L	pH 7 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.0000095 mol/L	pH 8 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.0000022 mol/L	pH 9 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.0000015 mol/L	pH 10 25 deg C	(1)
Molar Solubility (SLB.MOL)	0.0000044 mol/L	Unbuffered Water	(1)
		pH 8.43	
		25 deg C	
Molar Volume (MVOL)	529.2+/-3.0 cm**3/mol	20 deg C	(1)
		760 Torr	
Molecular Weight (MW)	568.74		(1)
pKa (PKA)	8.74+/-0.20	Most Basic	(1)
		25 deg C	
Polar Surface Area (PSA)	61.86 A**2		(1)
Vapor Pressure (VP)	6.95E-19 Torr	25 deg C	(1)

(1) Calculated using Advanced Chemistry Development (ACD/Labs) Software V8.14
((C) 1994-2006 ACD/Labs)

See HELP PROPERTIES for information about property data sources in REGISTRY.
6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	8.74	8.95

FILE 'REGISTRY' ENTERED AT 09:15:46 ON 23 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 MAR 2006 HIGHEST RN 877591-95-2
DICTIONARY FILE UPDATES: 21 MAR 2006 HIGHEST RN 877591-95-2

Erythropoietin production potentiator

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> SET TERMSET E#

SET COMMAND COMPLETED

=> DEL SEL Y

=> SEL L2 2 RN

E1 THROUGH E1 ASSIGNED

=> S E1/RN

L3 1 191089-59-5/RN

=> SET TERMSET LOGIN

SET COMMAND COMPLETED

=> FIL BIOSIS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.52

9.47

FILE 'BIOSIS' ENTERED AT 09:15:50 ON 23 MAR 2006
Copyright (c) 2006 The Thomson Corporation

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 22 March 2006 (20060322/ED)

=> S L3

Erythropoietin production potentiator

L4 6 L3

=> d L4 1-6 ti

L4 ANSWER 1 OF 6 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Oral administration of K-11706 inhibits GATA binding activity, enhances
hypoxia-inducible factor 1 binding activity, and restores indicators in an
in vivo mouse model of anemia of chronic disease.

L4 ANSWER 2 OF 6 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI A novel GATA-specific inhibitor (GSI) rescues anemia of chronic disease by
oral administration.

L4 ANSWER 3 OF 6 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI A NOVEL CELL ADHESION INHIBITOR, K - 7174, REDUCES LYMPHOCYTE INFILTRATION
AND INCREASES TEAR PRODUCTION IN SJOJREN'S SYNDROME MODEL MOUSE.

L4 ANSWER 4 OF 6 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta,
TNF-alpha, or L-NMMA.

L4 ANSWER 5 OF 6 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI GATA-Specific Inhibitor (K-7174) Rescues Anemia Induced by IL-1beta,
TNF-alpha or L-NMMA.

L4 ANSWER 6 OF 6 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1
induction by inflammatory cytokines, acting through the regulation of
GATA.

=> file	BIOSIS, CA, CAPLUS, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL
COST IN U.S. DOLLARS	SINCE FILE TOTAL
	ENTRY SESSION
FULL ESTIMATED COST	1.76 11.23

FILE 'BIOSIS' ENTERED AT 09:16:53 ON 23 MAR 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'CA' ENTERED AT 09:16:53 ON 23 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 09:16:53 ON 23 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PROUSDDR' ENTERED AT 09:16:53 ON 23 MAR 2006
COPYRIGHT (C) 2006 Prous Science

FILE 'SYNTHLINE' ENTERED AT 09:16:53 ON 23 MAR 2006
COPYRIGHT (C) 2006 Prous Science

FILE 'TOXCENTER' ENTERED AT 09:16:53 ON 23 MAR 2006
COPYRIGHT (C) 2006 ACS

FILE 'USPATFULL' ENTERED AT 09:16:53 ON 23 MAR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 191089-59-5/RN

Erythropoietin production potentiator

'RN' IS NOT A VALID FIELD CODE
NUMERIC VALUE NOT VALID '191089-59-5'
NUMERIC VALUE NOT VALID '191089-59-5'
'RN' IS NOT A VALID FIELD CODE
L5 13 191089-59-5/RN

=> s L5 and py<2003
'2003' NOT A VALID FIELD CODE
L6 7 L5 AND PY<2003

=> d L6 1-7 ti

L6 ANSWER 1 OF 7 CA COPYRIGHT 2006 ACS on STN
TI A Novel Cell Adhesion Inhibitor, K-7174, Reduces the Endothelial VCAM-1
Induction by Inflammatory Cytokines, Acting through the Regulation of GATA

L6 ANSWER 2 OF 7 CA COPYRIGHT 2006 ACS on STN
TI An inhibitor of VCAM-1 expression and its implication as a novel treatment
of inflammatory diseases

L6 ANSWER 3 OF 7 CA COPYRIGHT 2006 ACS on STN
TI Preparation of N,N'-bis(aralkenyl)piperazine and -homopiperazines as
inhibitors of cellular adhesion and infiltration.

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI A Novel Cell Adhesion Inhibitor, K-7174, Reduces the Endothelial VCAM-1
Induction by Inflammatory Cytokines, Acting through the Regulation of GATA

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI An inhibitor of VCAM-1 expression and its implication as a novel treatment
of inflammatory diseases

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of N,N'-bis(aralkenyl)piperazine and -homopiperazines as
inhibitors of cellular adhesion and infiltration.

L6 ANSWER 7 OF 7 USPATFULL on STN
TI Inhibitors for cell adhesion and cellular infiltration

=> d L6 1-7 ti abs bib


L6 ANSWER 1 OF 7 CA COPYRIGHT 2006 ACS on STN
TI A Novel Cell Adhesion Inhibitor, K-7174, Reduces the Endothelial VCAM-1
Induction by Inflammatory Cytokines, Acting through the Regulation of GATA
AB A novel inhibitor for the adhesion of monocytes to cytokine-stimulated
endothelial cells, K-7174, was selected by an assay system using the
cultured human monocytic cells and human endothelial cells. K-7174
inhibited the expression of vascular cell adhesion mol.-1 (VCAM-1) induced
by either tumor necrosis factor α or interleukin-1 β , without
affecting the induction of intercellular adhesion mol.-1 or E-selectin.
K-7174 had no effect on the stability of VCAM-1 mRNA. Electrophoretic
mobility shift assay revealed that its inhibitory effect on VCAM-1
induction was mediated by an effect on the binding to the GATA motifs in
the VCAM-1 gene promoter region. K-7174 did not influence the binding to
any of the following binding motifs: octamer binding protein, AP-1, SP-1,
ets, NF κ B, or interferon regulatory factor. These results suggest
that the regulation of GATA binding may become a new target for
anti-inflammatory drug development, acting through a mechanism independent
from NF κ B activity. (c) 2000 Academic Press.
AN 133:171963 CA
TI A Novel Cell Adhesion Inhibitor, K-7174, Reduces the Endothelial VCAM-1
Induction by Inflammatory Cytokines, Acting through the Regulation of GATA

Erythropoietin production potentiator

AU Umetani, Michihisa; Nakao, Hiroshi; Doi, Takeshi; Iwasaki, Akio; Ohtaka, Manami; Nagoya, Takao; Matakai, Chikage; Hamakubo, Takao; Kodama, Tatsuhiko
 CS Department of Molecular Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan
 SO Biochemical and Biophysical Research Communications (2000), 272(2), 370-374
 CODEN: BBRCA9; ISSN: 0006-291X
 PB Academic Press
 DT Journal
 LA English
 RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 7 CA COPYRIGHT 2006 ACS on STN
 TI An inhibitor of VCAM-1 expression and its implication as a novel treatment of inflammatory diseases
 AB To evaluate endothelial-leukocyte adhesion, we developed an adhesion technique using human umbilical vein endothelial cells (HUVECs) and U-937 cells. This technique clarified that ICAM-1 and VCAM-1 were primarily responsible for this adhesion. Using this technique, we found a low mol. weight compound that potently inhibits the adhesion through specifically suppressing the expression of VCAM-1 of HUVECs. When orally administered to mice, this compound also diminished the increase in paw thickness and in anti-bovine type II collagen (anti-BII) antibodies in mouse collagen-induced arthritis.
 AN 133:129534 CA
 TI An inhibitor of VCAM-1 expression and its implication as a novel treatment of inflammatory diseases
 AU Nakao, Hiroshi; Doi, Takeshi; Suda, Makoto; Umetani, Michihisa; Ohtaka, Manami; Shiratsuchi, Masami; Kodama, Tatsuhiko
 CS Department of Cell Biology, Kowa Research Institute, Ibaraki, 305-0856, Japan
 SO Journal of Atherosclerosis and Thrombosis (1998), 4(4), 149-155
 CODEN: JATHEH; ISSN: 1340-3478
 PB Japan Atherosclerosis Society
 DT Journal
 LA English
 RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 7 CA COPYRIGHT 2006 ACS on STN
 TI Preparation of N,N'-bis(aralkenyl)piperazine and -homopiperazines as inhibitors of cellular adhesion and infiltration.
 GI



AB Title compds. (I; X = (CH₂)_n; R₁-R₆ = H, halo, OH, alkyl, alkoxy; m = 1-3; n = 2, 3), were prepared. Thus, (E)-5-(3,4,5-trimethoxyphenyl)-4-pentenyl bromide, homopiperazine, K₂CO₃, KI, and DMF were heated at 100° to give N,N'-bis[(E)-(3,4,5-trimethoxyphenyl)-4-pentenyl]homopiperazine (II). II at 30 mg/kg i.p. in guinea pigs reduced infiltration of trachea by eosinocytes from 204.5 cells/mm to 122.2 cells/mm. II tablet and capsule formulations are given.

Erythropoietin production potentiator

AN 127:50669 CA
 TI Preparation of N,N'-bis(aralkenyl)piperazine and -homopiperazines as inhibitors of cellular adhesion and infiltration.
 IN Nakao, Hiroshi; Umetani, Michihisa; Suda, Makoto; Nagoya, Takao
 PA Kowa Co., Ltd., Japan
 SO Eur. Pat. Appl., 12 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 774257	A2	19970521	EP 1996-118463	19961118 <--
	EP 774257	A3	19970827		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09143075	A2	19970603	JP 1995-301526	19951120 <--
	US 5723465	A	19980303	US 1996-746811	19961118 <--
PRAI	JP 1995-301526	A	19951120		
OS	MARPAT 127:50669				

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 TI A Novel Cell Adhesion Inhibitor, K-7174, Reduces the Endothelial VCAM-1 Induction by Inflammatory Cytokines, Acting through the Regulation of GATA
 AB A novel inhibitor for the adhesion of monocytes to cytokine-stimulated endothelial cells, K-7174, was selected by an assay system using the cultured human monocytic cells and human endothelial cells. K-7174 inhibited the expression of vascular cell adhesion mol.-1 (VCAM-1) induced by either tumor necrosis factor α or interleukin-1 β , without affecting the induction of intercellular adhesion mol.-1 or E-selectin. K-7174 had no effect on the stability of VCAM-1 mRNA. Electrophoretic mobility shift assay revealed that its inhibitory effect on VCAM-1 induction was mediated by an effect on the binding to the GATA motifs in the VCAM-1 gene promoter region. K-7174 did not influence the binding to any of the following binding motifs: octamer binding protein, AP-1, SP-1, ets, NF κ B, or interferon regulatory factor. These results suggest that the regulation of GATA binding may become a new target for anti-inflammatory drug development, acting through a mechanism independent from NF κ B activity. (c) 2000 Academic Press.

AN 2000:369384 CAPLUS
 DN 133:171963
 TI A Novel Cell Adhesion Inhibitor, K-7174, Reduces the Endothelial VCAM-1 Induction by Inflammatory Cytokines, Acting through the Regulation of GATA
 AU Umetani, Michihisa; Nakao, Hiroshi; Doi, Takeshi; Iwasaki, Akio; Ohtaka, Manami; Nagoya, Takao; Matakai, Chikage; Hamakubo, Takao; Kodama, Tatsuhiko
 CS Department of Molecular Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan
 SO Biochemical and Biophysical Research Communications (2000), 272(2), 370-374
 CODEN: BBRCA9; ISSN: 0006-291X
 PB Academic Press
 DT Journal
 LA English
 RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 TI An inhibitor of VCAM-1 expression and its implication as a novel treatment of inflammatory diseases
 AB To evaluate endothelial-leukocyte adhesion, we developed an adhesion technique using human umbilical vein endothelial cells (HUVECs) and U-937 cells. This technique clarified that ICAM-1 and VCAM-1 were primarily responsible for this adhesion. Using this technique, we found a low mol.

Erythropoietin production potentiator

weight compound that potently inhibits the adhesion through specifically suppressing the expression of VCAM-1 of HUVECs. When orally administered to mice, this compound also diminished the increase in paw thickness and in anti-bovine type II collagen (anti-BII) antibodies in mouse collagen-induced arthritis.

AN 2000:228798 CAPLUS

DN 133:129534

TI An inhibitor of VCAM-1 expression and its implication as a novel treatment of inflammatory diseases

AU Nakao, Hiroshi; Doi, Takeshi; Suda, Makoto; Umetani, Michihisa; Ohtaka, Manami; Shiratsuchi, Masami; Kodama, Tatsuhiko

CS Department of Cell Biology, Kowa Research Institute, Ibaraki, 305-0856, Japan

SO Journal of Atherosclerosis and Thrombosis (1998), 4(4), 149-155

CODEN: JATHEH; ISSN: 1340-3478

PB Japan Atherosclerosis Society

DT Journal


LA English

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of N,N'-bis(aralkenyl)piperazine and -homopiperazines as inhibitors of cellular adhesion and infiltration.

GI



AB Title compds. (I; X = (CH₂)_n; R₁-R₆ = H, halo, OH, alkyl, alkoxy; m = 1-3; n = 2, 3), were prepared Thus, (E)-5-(3,4,5-trimethoxyphenyl)-4-pentenyl bromide, homopiperazine, K₂CO₃, KI, and DMF were heated at 100° to give N,N'-bis[(E)-(3,4,5-trimethoxyphenyl)-4-pentenyl]homopiperazine (II). II at 30 mg/kg i.p. in guinea pigs reduced infiltration of trachea by eosinocytes from 204.5 cells/mm to 122.2 cells/mm. II tablet and capsule formulations are given.

AN 1997:435944 CAPLUS

DN 127:50669

TI Preparation of N,N'-bis(aralkenyl)piperazine and -homopiperazines as inhibitors of cellular adhesion and infiltration.

IN Nakao, Hiroshi; Umetani, Michihisa; Suda, Makoto; Nagoya, Takao

PA Kowa Co., Ltd., Japan

SO Eur. Pat. Appl., 12 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 774257	A2	19970521	EP 1996-118463	19961118 <--
	EP 774257	A3	19970827		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09143075	A2	19970603	JP 1995-301526	19951120 <--
	US 5723465	A	19980303	US 1996-746811	19961118 <--

Erythropoietin production potentiator

PRAI JP 1995-301526 A 19951120
OS MARPAT 127:50669

L6 ANSWER 7 OF 7 USPATFULL on STN

TI Inhibitors for cell adhesion and cellular infiltration

AB The present invention is directed to a cell adhesion inhibitory agent, cellular infiltration inhibitory agent, antiallergic agent, antiasthmatic agent, and antiphlogistic, which contains a compound of the following formula (1): ##STR1## wherein each of R.sup.1 through R.sup.6 represents H, a halogen atom, a hydroxyl group, a lower alkyl group, or a lower alkoxy group, m represents a number of 1 from 3 inclusive, and n represents 2 or 3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:22225 USPATFULL

TI Inhibitors for cell adhesion and cellular infiltration

IN Nakao, Hiroshi, Tsuchiura, Japan

Umetani, Michihisa, Tokyo, Japan

Suda, Makoto, Tsukuba, Japan

Nagoya, Takao, Tsuchiura, Japan

PA Kowa Co., Ltd., Nagoya, Japan (non-U.S. corporation)

PI US 5723465 19980303

<--

AI US 1996-746811 19961118 (8)

PRAI JP 1995-301526 19951120

DT Utility

FS Granted

EXNAM Primary Examiner: Henley, III, Raymond

LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.

CLMN Number of Claims: 2

ECL Exemplary Claim: 2

DRWN No Drawings

LN.CNT 488

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 15 ti

L5 ANSWER 1 OF 13 CA COPYRIGHT 2006 ACS on STN

TI Trial of novel drug for secondary anemia from chronic disease

=> d 15 1-13 ti

L5 ANSWER 1 OF 13 CA COPYRIGHT 2006 ACS on STN

TI Trial of novel drug for secondary anemia from chronic disease

L5 ANSWER 2 OF 13 CA COPYRIGHT 2006 ACS on STN

TI Novel erythropoietin-stimulating drug (K-7174): Trial for renal anemia

L5 ANSWER 3 OF 13 CA COPYRIGHT 2006 ACS on STN

TI A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1 β , TNF- α , or L-NMMA

L5 ANSWER 4 OF 13 CA COPYRIGHT 2006 ACS on STN

TI A Novel Cell Adhesion Inhibitor, K-7174, Reduces the Endothelial VCAM-1 Induction by Inflammatory Cytokines, Acting through the Regulation of GATA

L5 ANSWER 5 OF 13 CA COPYRIGHT 2006 ACS on STN

TI An inhibitor of VCAM-1 expression and its implication as a novel treatment of inflammatory diseases

L5 ANSWER 6 OF 13 CA COPYRIGHT 2006 ACS on STN

TI Preparation of N,N'-bis(aralkenyl)piperazine and -homopiperazines as

Erythropoietin production potentiator

inhibitors of cellular adhesion and infiltration.

- L5 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
TI A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1 β , TNF- α , or L-NMMA
- L5 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
TI Trial of novel drug for secondary anemia from chronic disease
- L5 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
TI Novel erythropoietin-stimulating drug (K-7174): Trial for renal anemia
- L5 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
TI A Novel Cell Adhesion Inhibitor, K-7174, Reduces the Endothelial VCAM-1 Induction by Inflammatory Cytokines, Acting through the Regulation of GATA
- L5 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
TI An inhibitor of VCAM-1 expression and its implication as a novel treatment of inflammatory diseases
- L5 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of N,N'-bis(aralkenyl)piperazine and -homopiperazines as inhibitors of cellular adhesion and infiltration.
- L5 ANSWER 13 OF 13 USPATFULL on STN
TI Inhibitors for cell adhesion and cellular infiltration

=> s L5 and anemia

L7 6 L5 AND ANEMIA

=> d L7 1-6 ti abs bib

- L7 ANSWER 1 OF 6 CA COPYRIGHT 2006 ACS on STN
TI Trial of novel drug for secondary **anemia** from chronic disease
AB The GATA specific blocker K 7174 inhibited IL-1 β and TNF- α -induced GATA binding activity and increased erythropoietin formation in Hep3B cells. The results indicated that K 7174 may be useful for treatment of secondary **anemia** from chronic disease.
AN 139:345612 CA
TI Trial of novel drug for secondary **anemia** from chronic disease
AU Imagawa, Shigehiko; Nakano, Yoko; Obara, Naoshi; Suzuki, Norio; Doi, Takeshi; Kodama, Tatsuhiko; Nagasawa, Toshiro; Yamamoto, Masayuki
CS School of Clinical Medicine, University of Tsukuba, Tsukuba-shi, 305-8575, Japan
SO Igaku no Ayumi (2003), 204(12), 903-904
CODEN: IGAYAY; ISSN: 0039-2359
PB Ishiyaku Shuppan
DT Journal
LA Japanese
- L7 ANSWER 2 OF 6 CA COPYRIGHT 2006 ACS on STN
TI Novel erythropoietin-stimulating drug (K-7174): Trial for renal **anemia**
AB K-7174 stimulated erythropoietin activity in HEP3B by inhibiting GATA transcription factor in vitro. The results are discussed with regards to treatment of renal **anemia** by K-7174.
AN 139:317013 CA
TI Novel erythropoietin-stimulating drug (K-7174): Trial for renal **anemia**
AU Imagawa, Shigehiko; Nakano, Yoko; Obara, Naoshi; Suzuki, Norio; Doi, Takeshi; Kodama, Tatsuhiko; Yanagawa, Toshiro; Yamamoto, Masayuki
CS School of Clinical Medicine, University of Tsukuba, Japan

Erythropoietin production potentiator

SO Igaku no Ayumi (2003), 204(4), 291-292

CODEN: IGAYAY; ISSN: 0039-2359

PB Ishiyaku Shuppan

DT Journal

LA Japanese

L7 ANSWER 3 OF 6 CA COPYRIGHT 2006 ACS on STN

TI A GATA-specific inhibitor (K-7174) rescues **anemia** induced by [IL-1 β , TNF- α , or L-NMMA

AB Interleukin-1 β (IL-1 β), tumor necrosis factor- α (TNF- α), or NG-monomethyl-L-arginine (L-NMMA) are increased in patients with chronic disease-related **anemia**. They increase the binding activity of GATA and inhibit erythropoietin (Epo) promoter activity. In this study, we examined the ability of K-7174 (a GATA-specific inhibitor) to improve Epo production when inhibited by treatment with IL-1 β , TNF- α , or L-NMMA. Epo protein production and promoter activity were induced in Hep3B cells with 1% O₂. However, 15 U/mL IL-1 β , 220 U/mL TNF- α or 10⁻³ M L-NMMA inhibited Epo protein production and promoter activity, resp. Addition of 10 μ M K-7174 rescued these inhibitions of Epo protein production and promoter activity induced by IL-1 β , TNF- α , or L-NMMA, resp. Electrophoretic mobility shift assays revealed that addition of K-7174 decreased GATA binding activity, which was increased with the addition of IL-1 β , TNF- α , or L-NMMA. Furthermore, i.p. injection of mice with IL-1 β or TNF- α decreased the Hb concns. and reticulocyte counts. However, the addition of K-7174 reversed these effects. These results raise the possibility of using K-7174 as therapy to treat **anemia**.

AN 139:285954 CA

TI A GATA-specific inhibitor (K-7174) rescues **anemia** induced by IL-1 β , TNF- α , or L-NMMA

AU Imagawa, Shigehiko; Nakano, Yoko; Obara, Naoshi; Suzuki, Norio; Doi, Takeshi; Kodama, Tatsuhiko; Nagasawa, Toshiro; Yamamoto, Masayuki

CS Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, 305-8575, Japan

SO FASEB Journal (2003), 17(12), 1742-1744, 10.1096/fj.02-1134fje
CODEN: FAJOEC; ISSN: 0892-6638

PB Federation of American Societies for Experimental Biology

DT Journal

LA English

RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

TI A GATA-specific inhibitor (K-7174) rescues **anemia** induced by IL-1 β , TNF- α , or L-NMMA

AB Interleukin-1 β (IL-1 β), tumor necrosis factor- α (TNF- α), or NG-monomethyl-L-arginine (L-NMMA) are increased in patients with chronic disease-related **anemia**. They increase the binding activity of GATA and inhibit erythropoietin (Epo) promoter activity. In this study, we examined the ability of K-7174 (a GATA-specific inhibitor) to improve Epo production when inhibited by treatment with IL-1 β , TNF- α , or L-NMMA. Epo protein production and promoter activity were induced in Hep3B cells with 1% O₂. However, 15 U/mL IL-1 β , 220 U/mL TNF- α or 10⁻³ M L-NMMA inhibited Epo protein production and promoter activity, resp. Addition of 10 μ M K-7174 rescued these inhibitions of Epo protein production and promoter activity induced by IL-1 β , TNF- α , or L-NMMA, resp. Electrophoretic mobility shift assays revealed that addition of K-7174 decreased GATA binding activity, which was increased with the addition of IL-1 β , TNF- α , or L-NMMA. Furthermore, i.p. injection of mice with IL-1 β or TNF- α decreased the Hb concns. and reticulocyte counts. However, the addition of K-7174 reversed these effects. These results raise the possibility of using K-7174 as therapy to treat **anemia**.

Erythropoietin production potentiator

AN 2003:730740 CAPLUS
 DN 139:285954
 TI A GATA-specific inhibitor (K-7174) rescues **anemia** induced by
 IL-1 β , TNF- α , or L-NMMA
 AU Imagawa, Shigehiko; Nakano, Yoko; Obara, Naoshi; Suzuki, Norio; Doi,
 Takeshi; Kodama, Tatsuhiko; Nagasawa, Toshiro; Yamamoto, Masayuki
 CS Division of Hematology, Institute of Clinical Medicine, University of
 Tsukuba, Tsukuba, Ibaraki, 305-8575, Japan
 SO FASEB Journal (2003), 17(12), 1742-1744, 10.1096/fj.02-1134fje
 CODEN: FAJOEC; ISSN: 0892-6638
 PB Federation of American Societies for Experimental Biology
 DT Journal
 LA English
 RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Trial of novel drug for secondary **anemia** from chronic disease
 AB The GATA specific blocker K 7174 inhibited IL-1 β and
 TNF- α -induced GATA binding activity and increased erythropoietin
 formation in Hep3B cells. The results indicated that K 7174 may be useful
 for treatment of secondary **anemia** from chronic disease.

AN 2003:383581 CAPLUS
 DN 139:345612
 TI Trial of novel drug for secondary **anemia** from chronic disease
 AU Imagawa, Shigehiko; Nakano, Yoko; Obara, Naoshi; Suzuki, Norio; Doi,
 Takeshi; Kodama, Tatsuhiko; Nagasawa, Toshiro; Yamamoto, Masayuki
 CS School of Clinical Medicine, University of Tsukuba, Tsukuba-shi, 305-8575,
 Japan
 SO Igaku no Ayumi (2003), 204(12), 903-904
 CODEN: IGAYAY; ISSN: 0039-2359
 PB Ishiyaku Shuppan
 DT Journal
 LA Japanese

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Novel erythropoietin-stimulating drug (K-7174): Trial for renal
anemia
 AB K-7174 stimulated erythropoietin activity in HEP3B by inhibiting GATA
 transcription factor in vitro. The results are discussed with regards to
 treatment of renal **anemia** by K-7174.

AN 2003:298127 CAPLUS
 DN 139:317013
 TI Novel erythropoietin-stimulating drug (K-7174): Trial for renal
anemia
 AU Imagawa, Shigehiko; Nakano, Yoko; Obara, Naoshi; Suzuki, Norio; Doi,
 Takeshi; Kodama, Tatsuhiko; Yanagawa, Toshiro; Yamamoto, Masayuki
 CS School of Clinical Medicine, University of Tsukuba, Japan
 SO Igaku no Ayumi (2003), 204(4), 291-292
 CODEN: IGAYAY; ISSN: 0039-2359
 PB Ishiyaku Shuppan
 DT Journal
 LA Japanese

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
62.69	73.92

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-8.76	-8.76

CA SUBSCRIBER PRICE

Erythropoietin production potentiator

FILE 'STNGUIDE' ENTERED AT 09:20:39 ON 23 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 17, 2006 (20060317/UP).

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.18	74.10

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-8.76

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 09:22:13 ON 23 MAR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 21	IPC search and display fields enhanced in CA/CAPLUS with the IPC reform
NEWS	4	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2
NEWS	5	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	6	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	7	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	8	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	9	JAN 30	Saved answer limit increased
NEWS	10	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS	11	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	12	FEB 22	Status of current WO (PCT) information on STN
NEWS	13	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	14	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	15	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	16	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	17	FEB 28	TOXCENTER reloaded with enhancements
NEWS	18	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data